The personality traits activity, self-reproach, and negative affect jointly predict clinical recurrence, depressive symptoms, and low quality of life in inflammatory bowel disease patients.
Five-factor model
Flares
IBD
NEO-FFI
Personality
Journal
Journal of gastroenterology
ISSN: 1435-5922
Titre abrégé: J Gastroenterol
Pays: Japan
ID NLM: 9430794
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
25
02
2022
accepted:
24
06
2022
pubmed:
29
7
2022
medline:
28
10
2022
entrez:
28
7
2022
Statut:
ppublish
Résumé
The bidirectional "gut-brain axis" has been implicated in the pathogenesis of inflammatory bowel diseases (IBD). While the influence of stress and depressive symptoms on IBD is well-characterized, the role of personality remains insufficiently investigated. Personality was assessed in 1154 Swiss IBD cohort study (SIBDCS) patients via the NEO-Five-Factor Inventory (NEO-FFI) as well as in 2600 participants of the population-based CoLaus¦PsyCoLaus cohort study (NEO-FFI-revised). The NEO-FFI subcomponents activity, self-reproach and negative affect were associated with higher IBD disease activity and were combined to a NEO-FFI risk score. This risk score was validated and its effect on clinical IBD course and psychological endpoints was analysed in time-to-event and cumulative incidence analyses. In time-to-event analyses, a high NEO-FFI risk score was predictive for the clinical endpoints of new extraintestinal manifestation [EIM, adjusted hazard ratio (aHR) = 1.64, corrected p value (q) = 0.036] and two established composite flare endpoints (aHR = 1.53-1.63, q = 0.003-0.006) as well as for the psychological endpoints depressive symptoms (aHR = 7.06, q < 0.001) and low quality of life (aHR = 3.06, q < 0.001). Furthermore, cumulative incidence analyses showed that patients at high NEO-FFI risk experienced significantly more episodes of active disease, new EIMs, one of the flare endpoints, depressive episodes and low disease-related quality of life. Personalities of IBD patients showed only minor differences from the general population sample (Pearson's r = 0.03-0.14). Personality assessed by the NEO-FFI contained considerable predictive power for disease recurrence, depressive symptoms and low quality of life in IBD patients. Nevertheless, the personalities of IBD patients did not substantially differ from the general population.
Sections du résumé
BACKGROUND
The bidirectional "gut-brain axis" has been implicated in the pathogenesis of inflammatory bowel diseases (IBD). While the influence of stress and depressive symptoms on IBD is well-characterized, the role of personality remains insufficiently investigated.
METHODS
Personality was assessed in 1154 Swiss IBD cohort study (SIBDCS) patients via the NEO-Five-Factor Inventory (NEO-FFI) as well as in 2600 participants of the population-based CoLaus¦PsyCoLaus cohort study (NEO-FFI-revised). The NEO-FFI subcomponents activity, self-reproach and negative affect were associated with higher IBD disease activity and were combined to a NEO-FFI risk score. This risk score was validated and its effect on clinical IBD course and psychological endpoints was analysed in time-to-event and cumulative incidence analyses.
RESULTS
In time-to-event analyses, a high NEO-FFI risk score was predictive for the clinical endpoints of new extraintestinal manifestation [EIM, adjusted hazard ratio (aHR) = 1.64, corrected p value (q) = 0.036] and two established composite flare endpoints (aHR = 1.53-1.63, q = 0.003-0.006) as well as for the psychological endpoints depressive symptoms (aHR = 7.06, q < 0.001) and low quality of life (aHR = 3.06, q < 0.001). Furthermore, cumulative incidence analyses showed that patients at high NEO-FFI risk experienced significantly more episodes of active disease, new EIMs, one of the flare endpoints, depressive episodes and low disease-related quality of life. Personalities of IBD patients showed only minor differences from the general population sample (Pearson's r = 0.03-0.14).
CONCLUSIONS
Personality assessed by the NEO-FFI contained considerable predictive power for disease recurrence, depressive symptoms and low quality of life in IBD patients. Nevertheless, the personalities of IBD patients did not substantially differ from the general population.
Identifiants
pubmed: 35900592
doi: 10.1007/s00535-022-01902-7
pii: 10.1007/s00535-022-01902-7
pmc: PMC9596530
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
848-866Subventions
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CS30-148422
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 3200B0-105993
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 3200B0-118308
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CSCO-122661
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CS30-139468
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CS30-148401
Organisme : Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
ID : 33CS30-177535
Investigateurs
Claudia Anderegg
(C)
Peter Bauerfeind
(P)
Christoph Beglinger
(C)
Stefan Begré
(S)
Dominique Belli
(D)
José M Bengoa
(JM)
Luc Biedermann
(L)
Beat Bigler
(B)
Janek Binek
(J)
Mirjam Blattmann
(M)
Stephan Boehm
(S)
Jan Borovicka
(J)
Christian P Braegger
(CP)
Nora Brunner
(N)
Patrick Bühr
(P)
Bernard Burnand
(B)
Emanuel Burri
(E)
Sophie Buyse
(S)
Matthias Cremer
(M)
Dominique H Criblez
(DH)
Philippe de Saussure
(P)
Lukas Degen
(L)
Joakim Delarive
(J)
Christopher Doerig
(C)
Barbara Dora
(B)
Gian Dorta
(G)
Mara Egger
(M)
Tobias Ehmann
(T)
Ali El-Wafa
(A)
Matthias Engelmann
(M)
Jessica Ezri
(J)
Christian Felley
(C)
Markus Fliegner
(M)
Nicolas Fournier
(N)
Montserrat Fraga
(M)
Pascal Frei
(P)
Remus Frei
(R)
Michael Fried
(M)
Florian Froehlich
(F)
Christian Funk
(C)
Raoul Ivano Furlano
(RI)
Suzanne Gallot-Lavallée
(S)
Martin Geyer
(M)
Marc Girardin
(M)
Delphine Golay
(D)
Tanja Grandinetti
(T)
Beat Gysi
(B)
Horst Haack
(H)
Johannes Haarer
(J)
Beat Helbling
(B)
Peter Hengstler
(P)
Denise Herzog
(D)
Cyrill Hess
(C)
Klaas Heyland
(K)
Thomas Hinterleitner
(T)
Philippe Hiroz
(P)
Claudia Hirschi
(C)
Petr Hruz
(P)
Rika Iwata
(R)
Res Jost
(R)
Pascal Juillerat
(P)
Vera Kessler Brondolo
(VK)
Christina Knellwolf
(C)
Christoph Knoblauch
(C)
Henrik Köhler
(H)
Rebekka Koller
(R)
Claudia Krieger-Grübel
(C)
Gerd Kullak-Ublick
(G)
Patrizia Künzler
(P)
Markus Landolt
(M)
Rupprecht Lange
(R)
Frank Serge Lehmann
(FS)
Andrew Macpherson
(A)
Philippe Maerten
(P)
Michel H Maillard
(MH)
Christine Manser
(C)
Michael Manz
(M)
Urs Marbet
(U)
George Marx
(G)
Christoph Matter
(C)
Valérie McLin
(V)
Rémy Meier
(R)
Martina Mendanova
(M)
Christa Meyenberger
(C)
Pierre Michetti
(P)
Benjamin Misselwitz
(B)
Darius Moradpour
(D)
Bernhard Morell
(B)
Patrick Mosler
(P)
Christian Mottet
(C)
Christoph Müller
(C)
Pascal Müller
(P)
Beat Müllhaupt
(B)
Claudia Münger-Beyeler
(C)
Leilla Musso
(L)
Andreas Nagy
(A)
Michaela Neagu
(M)
Cristina Nichita
(C)
Jan Niess
(J)
Natacha Noël
(N)
Andreas Nydegger
(A)
Nicole Obialo
(N)
Carl Oneta
(C)
Cassandra Oropesa
(C)
Ueli Peter
(U)
Daniel Peternac
(D)
Laetitia Marie Petit
(LM)
Franziska Piccoli-Gfeller
(F)
Julia Beatrice Pilz
(JB)
Valérie Pittet
(V)
Nadia Raschle
(N)
Ronald Rentsch
(R)
Sophie Restellini
(S)
Jean-Pierre Richterich
(JP)
Sylvia Rihs
(S)
Marc Alain Ritz
(MA)
Jocelyn Roduit
(J)
Daniela Rogler
(D)
Gerhard Rogler
(G)
Jean-Benoît Rossel
(JB)
Markus Sagmeister
(M)
Gaby Saner
(G)
Bernhard Sauter
(B)
Mikael Sawatzki
(M)
Michela Schäppi
(M)
Michael Scharl
(M)
Martin Schelling
(M)
Susanne Schibli
(S)
Hugo Schlauri
(H)
Sybille Schmid Uebelhart
(SS)
Jean-François Schnegg
(JF)
Alain Schoepfer
(A)
Frank Seibold
(F)
Mariam Seirafi
(M)
Gian-Marco Semadeni
(GM)
David Semela
(D)
Arne Senning
(A)
Marc Sidler
(M)
Christiane Sokollik
(C)
Johannes Spalinger
(J)
Holger Spangenberger
(H)
Philippe Stadler
(P)
Michael Steuerwald
(M)
Alex Straumann
(A)
Bigna Straumann-Funk
(B)
Michael Sulz
(M)
Joël Thorens
(J)
Sarah Tiedemann
(S)
Radu Tutuian
(R)
Stephan Vavricka
(S)
Francesco Viani
(F)
Jürg Vögtlin
(J)
Roland von Känel
(R)
Alain Vonlaufen
(A)
Dominique Vouillamoz
(D)
Rachel Vulliamy
(R)
Jürg Wermuth
(J)
Helene Werner
(H)
Paul Wiesel
(P)
Reiner Wiest
(R)
Tina Wylie
(T)
Jonas Zeitz
(J)
Dorothee Zimmermann
(D)
Informations de copyright
© 2022. The Author(s).
Références
Collaborators GBDIBD. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990–2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Gastroenterol Hepatol. 2020;5:17–30.
doi: 10.1016/S2468-1253(19)30333-4
Windsor JW, Kaplan GG. Evolving epidemiology of IBD. Curr Gastroenterol Rep. 2019;21:40.
pubmed: 31338613
doi: 10.1007/s11894-019-0705-6
Guan Q. A comprehensive review and update on the pathogenesis of inflammatory bowel disease. J Immunol Res. 2019;2019:7247238.
pubmed: 31886308
pmcid: 6914932
doi: 10.1155/2019/7247238
Cryan JF, O’Riordan KJ, Cowan CSM, et al. The microbiota-gut-brain axis. Physiol Rev. 2019;99:1877–2013.
pubmed: 31460832
doi: 10.1152/physrev.00018.2018
Brzozowski B, Mazur-Bialy A, Pajdo R, et al. Mechanisms by which Stress affects the experimental and clinical inflammatory bowel disease (IBD): role of brain-gut axis. Curr Neuropharmacol. 2016;14:892–900.
pubmed: 27040468
pmcid: 5333596
doi: 10.2174/1570159X14666160404124127
Zhang YZ, Li YY. Inflammatory bowel disease: pathogenesis. World J Gastroenterol. 2014;20:91–9.
pubmed: 24415861
pmcid: 3886036
doi: 10.3748/wjg.v20.i1.91
Jordi SBU, Lang BM, Auschra B, et al. Depressive symptoms predict clinical recurrence of inflammatory bowel disease. Inflamm Bowel Dis. 2021;28:560–71.
doi: 10.1093/ibd/izab136
Mikocka-Walus A, Pittet V, Rossel JB, et al. Symptoms of depression and anxiety are independently associated with clinical recurrence of inflammatory bowel disease. Clin Gastroenterol Hepatol. 2016;14:829-35 e1.
pubmed: 26820402
doi: 10.1016/j.cgh.2015.12.045
Camara RJ, Lukas PS, Begre S, et al. Effects of social support on the clinical course of Crohn’s disease. Inflamm Bowel Dis. 2011;17:1277–86.
pubmed: 21560191
doi: 10.1002/ibd.21481
Soliemanifar O, Soleymanifar A, Afrisham R. Relationship between personality and biological reactivity to stress: a review. Psychiatry Investig. 2018;15:1100–14.
pubmed: 30602103
pmcid: 6318487
doi: 10.30773/pi.2018.10.14.2
Denollet J. DS14: standard assessment of negative affectivity, social inhibition, and Type D personality. Psychosom Med. 2005;67:89–97.
pubmed: 15673629
doi: 10.1097/01.psy.0000149256.81953.49
Jordi SBU, Botte F, Lang BM, et al. Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. Aliment Pharmacol Ther. 2021;54:53–67.
pubmed: 33975385
doi: 10.1111/apt.16365
Allport GW. Pattern and growth in personality. Holt, Reinhart & Winston; 1961. https://psycnet.apa.org/record/1962-04728-000
Widiger TA. The oxford handbook of the five factor model. Oxford: Oxford University Press; 2017. https://psycnet.apa.org/record/2017-30849-000
Jokela M, Batty GD, Nyberg ST, et al. Personality and all-cause mortality: individual-participant meta-analysis of 3,947 deaths in 76,150 adults. Am J Epidemiol. 2013;178:667–75.
pubmed: 23911610
pmcid: 3755650
doi: 10.1093/aje/kwt170
Lee HB, Offidani E, Ziegelstein RC, et al. Five-factor model personality traits as predictors of incident coronary heart disease in the community: a 10.5-year cohort study based on the Baltimore epidemiologic catchment area follow-up study. Psychosomatics. 2014;55:352–61.
pubmed: 24751113
doi: 10.1016/j.psym.2013.11.004
Alexander E. Psychosomatic medicine—its principles and applications. Am J Psychiatr. 1951;108:318-a.
doi: 10.1176/ajp.108.4.318-a
Pittet V, Michetti P, Mueller C, et al. Cohort profile update: the swiss inflammatory bowel disease cohort study (SIBDCS). Int J Epidemiol. 2019;48:385–6.
pubmed: 30689927
doi: 10.1093/ije/dyy298
Preisig M, Waeber G, Vollenweider P, et al. The PsyCoLaus study: methodology and characteristics of the sample of a population-based survey on psychiatric disorders and their association with genetic and cardiovascular risk factors. BMC Psychiatry. 2009;9:9.
pubmed: 19292899
pmcid: 2667506
doi: 10.1186/1471-244X-9-9
Pittet V, Juillerat P, Mottet C, et al. Cohort profile: the swiss inflammatory bowel disease cohort study (SIBDCS). Int J Epidemiol. 2009;38:922–31.
pubmed: 18782896
doi: 10.1093/ije/dyn180
Costa PT, McCrae RR. Revised NEO personality inventory (NEO-PI-R) and NEO five-factor inventory (NEO-FFI): Professional manual. Odessa, FL: Psychological Assessment Resources, Inc.; 1992.
Saucier G. Replicable item-cluster subcomponents in the NEO five-factor inventory. J Pers Assess. 1998;70:263–76.
pubmed: 9697330
doi: 10.1207/s15327752jpa7002_6
Chapman BP. Bandwidth and fidelity on the NEO-five factor inventory: replicability and reliability of saucier’s (1998) item cluster subcomponents. J Pers Assess. 2007;88:220–34.
pubmed: 17437386
doi: 10.1080/00223890701268082
Murray G, Rawlings D, Allen NB, et al. NEO five-factor inventory scores: psychometric properties in a community sample. Meas Eval Couns Dev. 2003;36:140–9.
doi: 10.1080/07481756.2003.11909738
McCrae RR, Costa PT. A contemplated revision of the NEO five-factor inventory. Pers Indiv Differ. 2004;36:587–96.
doi: 10.1016/S0191-8869(03)00118-1
Aluja A, Garcia O, Rossier J, et al. Comparison of the NEO-FFI, the NEO-FFI-R and an alternative short version of the NEO-PI-R (NEO-60) in Swiss and Spanish samples. Pers Indiv Differ. 2005;38:591–604.
doi: 10.1016/j.paid.2004.05.014
Snaith RP. The hospital anxiety and depression scale. Health Qual Life Outcomes. 2003;1:29.
pubmed: 12914662
pmcid: 183845
doi: 10.1186/1477-7525-1-29
Janke KH, Klump B, Steder-Neukamm U, et al. Validation of the German version of the inflammatory bowel disease questionnaire (competence network IBD, IBDQ-D). Psychother Psychosom Med Psychol. 2006;56:291–8.
pubmed: 16715461
doi: 10.1055/s-2006-932661
Clinical Review Report: adalimumab (Humira). Ottawa (ON). 2016.
Huoponen S, Eberl A, Rasanen P, et al. Health-related quality of life and costs of switching originator infliximab to biosimilar one in treatment of inflammatory bowel disease. Medicine (Baltimore). 2020;99: e18723.
doi: 10.1097/MD.0000000000018723
Irvine EJ, Feagan B, Rochon J, et al. Quality of life: a valid and reliable measure of therapeutic efficacy in the treatment of inflammatory bowel disease. Canadian Crohn’s relapse prevention trial study group. Gastroenterology. 1994;106:287–96.
pubmed: 8299896
doi: 10.1016/0016-5085(94)90585-1
Lashner B, Brzezinski A. Crohn’s disease. GI/Liver Secrets. 2010. 297–303. https://doi.org/10.1016/B978-0-323-06397-5.00042-3 .
doi: 10.1016/B978-0-323-06397-5.00042-3
Lichtiger S, Present DH, Kornbluth A, et al. Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med. 1994;330:1841–5.
pubmed: 8196726
doi: 10.1056/NEJM199406303302601
Pek J, Wong O, Wong ACM. How to address non-normality: a taxonomy of approaches, reviewed, and illustrated. Front Psychol. 2018;9:2104.
pubmed: 30459683
pmcid: 6232275
doi: 10.3389/fpsyg.2018.02104
Therneau TM. A Package for Survival Analysis in R. R package version 3.3-1; 2022. https://CRAN.R-project.org/package=survival
Dong H, Robison LL, Leisenring WM, et al. Estimating the burden of recurrent events in the presence of competing risks: the method of mean cumulative count. Am J Epidemiol. 2015;181:532–40.
pubmed: 25693770
pmcid: 4371763
doi: 10.1093/aje/kwu289
Knowles SR, Graff LA, Wilding H, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part I. Inflamm Bowel Dis. 2018;24:742–51.
pubmed: 29562277
doi: 10.1093/ibd/izx100
Knowles SR, Keefer L, Wilding H, et al. Quality of life in inflammatory bowel disease: a systematic review and meta-analyses-part II. Inflamm Bowel Dis. 2018;24:966–76.
pubmed: 29688466
doi: 10.1093/ibd/izy015
Calvino-Suarez C, Ferreiro-Iglesias R, Baston-Rey I, et al. Role of quality of life as endpoint for inflammatory bowel disease treatment. Int J Environ Res Public Health. 2021;18:7159.
pubmed: 34281095
pmcid: 8296948
doi: 10.3390/ijerph18137159
Edenfield TM, Blumenthal JA. Exercise and stress reduction. In: The handbook of stress science: Biology, psychology, and health. New York, NY, US: Springer Publishing Company; 2011. p. 301–19.
Polak EJ, O’Callaghan F, Oaten M. Perceptions of IBD within patient and community samples: a systematic review. Psychol Health. 2020;35:425–48.
pubmed: 31538517
doi: 10.1080/08870446.2019.1662014
Bernstein CN. The brain-gut axis and stress in inflammatory bowel disease. Gastroenterol Clin North Am. 2017;46:839–46.
pubmed: 29173525
doi: 10.1016/j.gtc.2017.08.006
Humbel F, Rieder JH, Franc Y, et al. Association of alterations in intestinal microbiota with impaired psychological function in patients with inflammatory bowel diseases in remission. Clin Gastroenterol Hepatol. 2020;18(2019–29): e11.
Grande G, Romppel M, Glaesmer H, et al. The type-D scale (DS14) - Norms and prevalence of type-D personality in a population-based representative sample in Germany. Pers Indiv Differ. 2010;48:935–9.
doi: 10.1016/j.paid.2010.02.026
Costa PT Jr, McCrae RR, Lockenhoff CE. Personality across the life span. Annu Rev Psychol. 2019;70:423–48.
pubmed: 30231002
doi: 10.1146/annurev-psych-010418-103244
Jokela M, Hakulinen C, Singh-Manoux A, et al. Personality change associated with chronic diseases: pooled analysis of four prospective cohort studies. Psychol Med. 2014;44:2629–40.
pubmed: 25055176
doi: 10.1017/S0033291714000257
Weaver E, Szigethy E. Managing pain and psychosocial care in IBD: a primer for the practicing gastroenterologist. Curr Gastroenterol Rep. 2020;22:20.
pubmed: 32185521
doi: 10.1007/s11894-020-0757-7